Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Trizuljak J., Sperr W. R., Nekvindova L., Elberink H. O., Gleixner K., Gorska A., ...More

ALLERGY, vol.75, no.8, pp.1927-1938, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 75 Issue: 8
  • Publication Date: 2020
  • Doi Number: 10.1111/all.14248
  • Journal Name: ALLERGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1927-1938
  • Istanbul University Affiliated: No


Background: In indolent systemic mastocytosis (ISM), several risk factors of disease progression have been identified. Previous studies, performed with limited patient numbers, have also shown that the clinical course in ISM is stable and comparable to that of cutaneous mastocytosis (CM). The aim of this project was to compare the prognosis of patients with ISM with that of patients with CM.